Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update

Slide: 22 of 40

Benefits of Medications in Subpopulations

Patients with high risk for fracture (including postmenopausal women with osteoporosis) are likely to benefit from alendronate, denosumab, ibandronate, risedronate, teriparatide, raloxifene, and zoledronic acid. The strength of evidence for these findings is high.

Patients treated with glucocorticoids are likely to benefit from alendronate, risedronate, and teriparatide. The strength of evidence for these findings is low to moderate.

Patients with a higher risk of falling (e.g., patients with hemiplegia, Alzheimer’s disease, or Parkinson’s disease) are likely to benefit from alendronate, risedronate, and vitamin D. The strength of evidence for these findings is moderate.

For transplant recipients and patients treated chronically with corticosteroids, there is inconclusive support for any agent, and the evidence is insufficient to permit conclusions.

The risk of fragility fracture is reduced in postmenopausal women with osteopenia who do not have prevalent vertebral fractures when treated with risendronate. The strength of evidence for this finding is low to moderate.